搜尋

file (3)

What We Do

學術發表

首頁學術發表

2026.Apr.18

Technology

Hydrophilicity-Enhanced Linker Technology Enables Site-Specific Degrader–Antibody Conjugates with Improved Stability and Enhanced Activity

Poster

2026.Apr.18

Technology

Cell based payload release highlights design, site, and cell dependent ratio shifts in dual payload ADCs

Poster

2026.Apr.18

ADC

The MET/HER3 Antibody–Drug Conjugate: A Dual-Target Approach to Eliminate Tumor Escape Mechanisms

Poster

2026.Apr.18

ADC

OBI-904, a glycan-based site-specific Nectin-4–targeted ADC, demonstrates potent and durable antitumor activity with an improved PK profile and overcomes EV-resistance in non-clinical studies

Poster

2026.Apr.18

Technology

Advancing ADC Therapeutics with Next-generation Site-Specific Glycan Conjugation and Dual-Payload Flexibility

Poster

2026.Apr.18

ADC

TROP2 Upregulation and Interaction with HER2 Mediate Trastuzumab Resistance

Poster

2026.Apr.18

ADC

Overcoming resistance with OBI-902: Preclinical evaluation of a next-generation TROP2 ADC

Poster

2026.Apr.18

ADC

OBI-904, a next-generation nectin-4-targeting exatecan ADC, demonstrates enhanced cytotoxicity and overcomes enfortumab vedotin resistance

Poster

2026.Apr.18

ADC

Glycan conjugated ADC Achieves Sustained Tumor Control through Improved Payload Delivery and Immune Activation

Poster

2026.Apr.18

ADC

Guide-effector bsADCs: Driving co-endocytosis for enhanced payload delivery

Poster